HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

At Nuvothera, Rx Derma Veterans Develop OTCs For Serious Skin Conditions

Executive Summary

Firm launched Prosoria in 2018 as a four-product topical line for inflammatory autoimmune disease psoriasis containing salicylic acid 3% combined with turmeric and other botanicals. CEO Arthur Clapp says firm will launch turmeric supplements and plans adding products for acne, eczema, warts, nail fungus and rosacea.

You may also be interested in...



Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval

Galderma Labs' adapalene gel is pending launch as first OTC acne ingredient approved through an NDA and first new acne ingredient available OTC in 20 years, but company must play in a digitally-oriented marketplace.

L’Oréal Tackles Age-Old Problems With Home Hair Color, Spurred By Pandemic Demand

The French beauty giant plans to launch its Colorsonic at-home hair color device with oscillating nozzle in early 2023. L’Oreal showcased the product, along with a breakthrough hair color “reader” and custom mixing system for salon use, at the CES 2022 tech show in Las Vegas.

Beauty M&A In 2021 Vies With Pre-Pandemic Levels: Capstone Partners Discusses

Beauty merger and acquisition activity accelerated in the US last year, with 75 deals by mid-October 2021, versus 48 in the prior-year period, according to investment banking firm Capstone Partners’ recent Beauty & Wellness report.

Topics

Related Companies

UsernamePublicRestriction

Register

RS148540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel